Latest News

MGI Announces Commercial Availability of DNBSEQ™ Sequencers* in the United States

SAN JOSE, Calif., June 6, 2022 /PRNewswire/ -- MGI Americas (MGI), today announced that its innovative CoolMPS sequencing chemistry and instruments* will become commercially available inthe United States beginning from August 29,2022. More details about the launch will be revealed at the 22nd ...

2022-06-07 00:59 2750

Techman Robot to Showcase Newly Upgraded TM Robot S at Automate 2022

DETROIT, June 6, 2022 /PRNewswire/ -- Techman Robot, the second largest collaborative robot brand in the world, will showcase the newly upgraded TM Robot S and smart manufacturing solutions at Automate. The upgraded TM Robot S will have comprehensive hardware and software enhancements; smarter in...

2022-06-06 22:39 3321

Raythink receives IATF16949 quality management system certification

SHENZHEN, China, June 6, 2022 /PRNewswire/ -- Raythink, a world-leading ARHUD solution provider for the automotive and transportation industry, announced that the company has obtained the IATF16949 Quality Management System standard certification for the automotive industry.

2022-06-06 21:30 2912

The 2022 International MICE Culture Event and Global Digital Exhibition and Event Summit comes to a successful conclusion in Hangzhou

HANGZHOU, China, June 6, 2022 /PRNewswire/ -- In celebration of the Global Exhibitions Day (GED) onJune 1, 2022, Hangzhou Municipal People's Government joined hands with Trade Development Bureau of the Ministry of Commerce, International Association of Exhibitions and Events® (IAEE), and Hangzhou...

2022-06-06 21:20 2751

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Highlights * IND approval received for SAR-Bombesin product, enabling a Phase II "SABRE" imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US * Approximately 20% of prostate cancer patients with biochemical recurrence (BCR) are PSMA-PET negative and theref...

2022-06-06 21:08 3138

ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022

SHANGHAI, June 6, 2022  /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an international randomized phase 3 study (ASTRUM-005) of HANSIZHUANG (serplulimab), an anti-PD-1 mAb independently developed by Henlius, as first-line treatment for extensive-stage small-cell lung can...

2022-06-06 21:00 3261

Bedsure Releases a New Cooling Blanket That is Twice as Effective.

DIAMOND BAR, Calif. , June 6, 2022 /PRNewswire/ -- Bedsure, a global leading home textile manufacturer with over 18 million cozy customers served worldwide, releases a new upgrade to the well-received Bedsure Cooling Blanket to help customers beat the heat and stay cozy in the summer season. Rel...

2022-06-06 21:00 2799

Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

TAIPEI and SAN DIEGO, June 6, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that it has received written approval from the Human Research Ethics Committ...

2022-06-06 21:00 3121

CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual M...

2022-06-06 20:50 3907

Cango Inc. to Report First Quarter 2022 Financial Results on June 9, 2022 Eastern Time

SHANGHAI, June 6, 2022 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading automotive transaction service platform inChina, today announced that it plans to release its first quarter 2022 financial results after the market closes onThursday, June 9, 2022. The earnings re...

2022-06-06 20:00 2543

AP Memory launches brand-new product series of 512Mb Ultra-High-Speed (UHS) and 32Mb Ultra-Low-Swing (ULS) PSRAM

HSINCHU, June 6, 2022 /PRNewswire/ -- AP Memory, the global leading design company that provides customized memory solution, has announced today the launch of its new Ultra High Speed (UHS) and Ultra Low Swing (ULS) PSRAM. AP Memory rolls out AP351216C/AP351208, to further expand the density of A...

2022-06-06 20:00 3995

Canadian Solar Sells to SPIC Brasil 70% Stake in 738 MWp Solar Projects

GUELPH, ON, June 6, 2022 /PRNewswire/ -- Canadian Solar Inc.  ("Canadian Solar" or the "Company") (NASDAQ: CSIQ), today announced it signed an agreement with SPIC Brasil, a leading power generation company inBrazil, to sell 70% stake in the Company's 738 MWp solar ...

2022-06-06 19:00 2631

Futu Holdings Achieves Solid First-Quarter Growth Amid Market Volatility with 67.9% YoY Increase in Paying Clients

- Flagship trading apps moomoo and Futubull have acquired 18.1 million global users as of quarter end PALO ALTO, Calif., June 6, 2022 /PRNewswire/ -- Moomoo's parent company Futu Holdings Limited (Nasdaq: FUTU) (Futu), a leading tech-driven online brokerage and wealth management platform, r...

2022-06-06 18:00 4455

Tuya to Report First Quarter 2022 Financial Results on June 14, 2022 Eastern Time

SANTA CLARA, Calif., June 6, 2022  /PRNewswire/ -- Tuya Inc. ("Tuya" or the "Company") (NYSE: TUYA), a global leading IoT cloud development platform, today announced that it will report its first quarter 2022 unaudited financial results after the market closes onTuesday, June 14, 2022. Tuya's ma...

2022-06-06 18:00 2319

Boqii Announces Fourth Quarter and Full Fiscal Year 2022 Unaudited Financial Results

Fourth Quarter Revenues of RMB249.9 million, up 8.4% year-over-year Full Year Revenues of RMB1,186.4 million, up 17.4 % year-over-year SHANGHAI, June 6, 2022 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE: BQ), a leading pet-focused platform inChina, today announced its u...

2022-06-06 17:30 3864

Weibo Announces Results of 2022 Annual General Meeting

BEIJING, June 6, 2022 /PRNewswire/ -- Weibo Corporation ("Weibo" or the "Company") (NASDAQ: WB and HKEX: 9898), a leading social media inChina, today announced that the following proposed resolutions submitted for shareholder approval have been adopted at its 2022 annual general meeting of shareh...

2022-06-06 17:00 3713

Central China's Yichang City holds the Qu Yuan's hometown Dragon Boat Culture Festival

YICHANG, China, June 6, 2022 /PRNewswire/ -- "Qu Yuan belongs not only to Yichang City, but also the world and all mankind,"Wang Li, vice governor of centralChina's Hubei Province and top official of Yichang City, said emotionally as he addressed the opening ceremony of the 2022 Qu Yuan's Hometow...

2022-06-06 16:24 3079

"Captain Tsubasa: Dream Team" 5th Anniversary Kicks Off & New Players Wearing the JUVENTUS Official Kit Debut

TOKYO, June 6, 2022 /PRNewswire/ -- KLab Inc., a leader in online mobile games, announced that its head-to-head football simulation gameCaptain Tsubasa: Dream Teamkicked off its special 5th Anniversary with the JUVENTUS OFFICIAL CAMPAIGN: Gifts for All and more in-game campaigns onFriday, June 3....

2022-06-06 15:15 3099

Winmate's new 14"rugged tablet delivers an extensive experience on a big screen for the harshest environments

The Winmate M140TG Rugged Extreme is the most potent 14-inch fully rugged tablet available TAIPEI, June 6, 2022 /PRNewswire/ -- Winmate, a rugged computing industry leader, announced its new M140TG 14-inch extreme rugged tablet designed to provide field users mobility and connectivity needed to ...

2022-06-06 13:35 2965

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...

2022-06-06 12:23 3393